Consequently, the ADO pathway holds represents a complementary strategy to conventional immune checkpoint inhibitors, particularly for tumors exhibiting robust immunosuppressive features or resistance to existing therapies, thus providing a novel avenue for advancing cancer treatment. Here, ADO is linked to cancer.